Home

David Lebwohl

CIK 1810882 · EVP, Chief Medical Officer · last filed 2026-03-03

David Lebwohl is an EVP, Chief Medical Officer who has filed 21 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for NTLA, was dated Mar 3, 2026. Across all open-market trades the lifetime net is −$2.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.67M

Companies

1

Total Filings

21

Lifetime Open-Market Net

-$2.37M

Filer Profile

Reported Address
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET, SUITE 130
CAMBRIDGE, MA 02139
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NTLA EVP, Chief Medical Officer 131,192 $12.74 $1.67M -$2.37M 21 2026-03-03

Recent Filings

21 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-03 NTLA Grant (A) +9,943 $0 EDGAR
2026-01-07 NTLA Sell (S) −11,903 -$109.6K EDGAR
2025-03-04 NTLA Grant (A) +43,200 $0 EDGAR
2025-01-07 NTLA Sell (S) −9,557 -$116.4K EDGAR
2025-01-03 NTLA Exer (M) +3,189 $0 EDGAR
2024-03-05 NTLA Grant (A) +38,701 $0 EDGAR
2024-01-05 NTLA Sell (S) −5,843 -$172.1K EDGAR
2024-01-03 NTLA Exer (M) +3,187 $0 EDGAR
2023-03-03 NTLA Grant (A) +30,674 $0 EDGAR
2023-01-06 NTLA Sell (S) −2,574 -$95.8K EDGAR
Showing 1–10 of 21
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.